Doximity Shares Surge More Than 50% as Clinical AI Adoption Accelerates

Doximity shares surged more than 50% in Friday trading as investors focused on rapid adoption of the healthcare-software company’s artificial-intelligence products.

Fiscal first-quarter revenue reached $156.6 million, up 7% from a year earlier. But the strongest reaction followed management’s discussion of AI tools being integrated into physicians’ existing workflows.

Doximity’s AI-powered clinical scribe has experienced roughly tenfold year-over-year user growth, according to management. The company is also expanding Doximity Ask, an AI assistant designed for clinical questions and medical research.

An independent evaluation led by researchers associated with Stanford and Harvard medical schools recently ranked Doximity Ask first among the systems evaluated on a real-world clinical-safety benchmark, according to Doximity.

The results illustrate an important development in enterprise AI. General-purpose models dominate public attention, but specialized AI applications may have stronger commercial defensibility when they are embedded directly into professional workflows, proprietary datasets and existing customer networks.

Doximity already operates a large professional platform for U.S. physicians, giving it a built-in distribution channel for clinical AI products. The stock reaction suggests investors increasingly see that distribution advantage, not just model performance, as a potential competitive moat.